WO2010057765A1 - Process for the preparation of iodinated contrast agent - Google Patents
Process for the preparation of iodinated contrast agent Download PDFInfo
- Publication number
- WO2010057765A1 WO2010057765A1 PCT/EP2009/064413 EP2009064413W WO2010057765A1 WO 2010057765 A1 WO2010057765 A1 WO 2010057765A1 EP 2009064413 W EP2009064413 W EP 2009064413W WO 2010057765 A1 WO2010057765 A1 WO 2010057765A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- formula
- compound
- reaction
- hydroxide
- amino
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims abstract description 50
- 238000002360 preparation method Methods 0.000 title claims abstract description 31
- 239000002872 contrast media Substances 0.000 title abstract description 8
- 150000001875 compounds Chemical class 0.000 claims abstract description 55
- 238000006243 chemical reaction Methods 0.000 claims abstract description 45
- 229960004647 iopamidol Drugs 0.000 claims abstract description 37
- XQZXYNRDCRIARQ-LURJTMIESA-N iopamidol Chemical compound C[C@H](O)C(=O)NC1=C(I)C(C(=O)NC(CO)CO)=C(I)C(C(=O)NC(CO)CO)=C1I XQZXYNRDCRIARQ-LURJTMIESA-N 0.000 claims abstract description 35
- XLYOFNOQVPJJNP-UHFFFAOYSA-M hydroxide Chemical compound [OH-] XLYOFNOQVPJJNP-UHFFFAOYSA-M 0.000 claims abstract description 15
- 239000002904 solvent Substances 0.000 claims abstract description 14
- 238000006482 condensation reaction Methods 0.000 claims abstract description 11
- 229910000000 metal hydroxide Inorganic materials 0.000 claims abstract description 8
- 229910001404 rare earth metal oxide Inorganic materials 0.000 claims abstract description 7
- HEMHJVSKTPXQMS-UHFFFAOYSA-M sodium hydroxide Inorganic materials [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims description 33
- FXHOOIRPVKKKFG-UHFFFAOYSA-N N,N-Dimethylacetamide Chemical group CN(C)C(C)=O FXHOOIRPVKKKFG-UHFFFAOYSA-N 0.000 claims description 32
- 239000002253 acid Substances 0.000 claims description 24
- AXCZMVOFGPJBDE-UHFFFAOYSA-L calcium dihydroxide Chemical compound [OH-].[OH-].[Ca+2] AXCZMVOFGPJBDE-UHFFFAOYSA-L 0.000 claims description 17
- 239000000920 calcium hydroxide Substances 0.000 claims description 17
- 229910001861 calcium hydroxide Inorganic materials 0.000 claims description 17
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 claims description 16
- 125000000217 alkyl group Chemical group 0.000 claims description 8
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 8
- 239000003960 organic solvent Substances 0.000 claims description 8
- 235000019260 propionic acid Nutrition 0.000 claims description 8
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 claims description 8
- AVXURJPOCDRRFD-UHFFFAOYSA-N Hydroxylamine Chemical compound ON AVXURJPOCDRRFD-UHFFFAOYSA-N 0.000 claims description 5
- BRPQOXSCLDDYGP-UHFFFAOYSA-N calcium oxide Chemical compound [O-2].[Ca+2] BRPQOXSCLDDYGP-UHFFFAOYSA-N 0.000 claims description 5
- 239000000292 calcium oxide Substances 0.000 claims description 5
- ODINCKMPIJJUCX-UHFFFAOYSA-N calcium oxide Inorganic materials [Ca]=O ODINCKMPIJJUCX-UHFFFAOYSA-N 0.000 claims description 5
- 125000004432 carbon atom Chemical group C* 0.000 claims description 5
- 230000007062 hydrolysis Effects 0.000 claims description 5
- 238000006460 hydrolysis reaction Methods 0.000 claims description 5
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 4
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 4
- 229910052761 rare earth metal Inorganic materials 0.000 claims description 4
- 150000002910 rare earth metals Chemical class 0.000 claims description 4
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical group C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims description 3
- CBOIHMRHGLHBPB-UHFFFAOYSA-N hydroxymethyl Chemical compound O[CH2] CBOIHMRHGLHBPB-UHFFFAOYSA-N 0.000 claims description 3
- 239000000395 magnesium oxide Substances 0.000 claims description 3
- CPLXHLVBOLITMK-UHFFFAOYSA-N magnesium oxide Inorganic materials [Mg]=O CPLXHLVBOLITMK-UHFFFAOYSA-N 0.000 claims description 3
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical group [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 claims description 2
- 125000005842 heteroatom Chemical group 0.000 claims description 2
- KJJPLEZQSCZCKE-UHFFFAOYSA-N 2-aminopropane-1,3-diol Chemical compound OCC(N)CO KJJPLEZQSCZCKE-UHFFFAOYSA-N 0.000 abstract description 4
- 239000000243 solution Substances 0.000 description 26
- 238000007792 addition Methods 0.000 description 19
- 239000000203 mixture Substances 0.000 description 19
- 239000011541 reaction mixture Substances 0.000 description 16
- BTANRVKWQNVYAZ-UHFFFAOYSA-N butan-2-ol Chemical compound CCC(C)O BTANRVKWQNVYAZ-UHFFFAOYSA-N 0.000 description 15
- 239000012535 impurity Substances 0.000 description 15
- 239000000463 material Substances 0.000 description 15
- 238000003756 stirring Methods 0.000 description 13
- 229920005989 resin Polymers 0.000 description 11
- 239000011347 resin Substances 0.000 description 11
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 9
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 9
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 8
- 238000000746 purification Methods 0.000 description 8
- 238000004128 high performance liquid chromatography Methods 0.000 description 7
- 239000000047 product Substances 0.000 description 7
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 6
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 6
- -1 aliphatic tertiary amines Chemical class 0.000 description 6
- 235000012255 calcium oxide Nutrition 0.000 description 5
- 125000002091 cationic group Chemical group 0.000 description 5
- 150000007529 inorganic bases Chemical class 0.000 description 5
- 239000000543 intermediate Substances 0.000 description 5
- 238000006386 neutralization reaction Methods 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- DRSHXJFUUPIBHX-UHFFFAOYSA-N COc1ccc(cc1)N1N=CC2C=NC(Nc3cc(OC)c(OC)c(OCCCN4CCN(C)CC4)c3)=NC12 Chemical compound COc1ccc(cc1)N1N=CC2C=NC(Nc3cc(OC)c(OC)c(OCCCN4CCN(C)CC4)c3)=NC12 DRSHXJFUUPIBHX-UHFFFAOYSA-N 0.000 description 4
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 4
- 125000003668 acetyloxy group Chemical group [H]C([H])([H])C(=O)O[*] 0.000 description 4
- 239000012467 final product Substances 0.000 description 4
- 235000012245 magnesium oxide Nutrition 0.000 description 4
- 229920001467 poly(styrenesulfonates) Polymers 0.000 description 4
- GEHJYWRUCIMESM-UHFFFAOYSA-L sodium sulfite Chemical compound [Na+].[Na+].[O-]S([O-])=O GEHJYWRUCIMESM-UHFFFAOYSA-L 0.000 description 4
- 238000003786 synthesis reaction Methods 0.000 description 4
- 150000003512 tertiary amines Chemical class 0.000 description 4
- 239000007864 aqueous solution Substances 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 239000006227 byproduct Substances 0.000 description 3
- 230000008025 crystallization Effects 0.000 description 3
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 3
- ZZUFCTLCJUWOSV-UHFFFAOYSA-N furosemide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC(C(O)=O)=C1NCC1=CC=CO1 ZZUFCTLCJUWOSV-UHFFFAOYSA-N 0.000 description 3
- 238000002955 isolation Methods 0.000 description 3
- AXZKOIWUVFPNLO-UHFFFAOYSA-N magnesium;oxygen(2-) Chemical class [O-2].[Mg+2] AXZKOIWUVFPNLO-UHFFFAOYSA-N 0.000 description 3
- 238000001728 nano-filtration Methods 0.000 description 3
- 229910000029 sodium carbonate Inorganic materials 0.000 description 3
- KQIGMPWTAHJUMN-UHFFFAOYSA-N 3-aminopropane-1,2-diol Chemical compound NCC(O)CO KQIGMPWTAHJUMN-UHFFFAOYSA-N 0.000 description 2
- NBDAHKQJXVLAID-UHFFFAOYSA-N 5-nitroisophthalic acid Chemical compound OC(=O)C1=CC(C(O)=O)=CC([N+]([O-])=O)=C1 NBDAHKQJXVLAID-UHFFFAOYSA-N 0.000 description 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 2
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 2
- 238000007112 amidation reaction Methods 0.000 description 2
- 239000003957 anion exchange resin Substances 0.000 description 2
- 229920001429 chelating resin Polymers 0.000 description 2
- 230000000052 comparative effect Effects 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- 238000002425 crystallisation Methods 0.000 description 2
- 239000008367 deionised water Substances 0.000 description 2
- 238000011033 desalting Methods 0.000 description 2
- 235000019439 ethyl acetate Nutrition 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 150000004679 hydroxides Chemical class 0.000 description 2
- 229910044991 metal oxide Inorganic materials 0.000 description 2
- 150000004706 metal oxides Chemical class 0.000 description 2
- 229920003053 polystyrene-divinylbenzene Polymers 0.000 description 2
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 2
- RZWZRACFZGVKFM-UHFFFAOYSA-N propanoyl chloride Chemical compound CCC(Cl)=O RZWZRACFZGVKFM-UHFFFAOYSA-N 0.000 description 2
- 125000006239 protecting group Chemical group 0.000 description 2
- 239000002994 raw material Substances 0.000 description 2
- 230000035484 reaction time Effects 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 235000010265 sodium sulphite Nutrition 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 239000007858 starting material Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- AMDBBAQNWSUWGN-UHFFFAOYSA-N Ioversol Chemical compound OCCN(C(=O)CO)C1=C(I)C(C(=O)NCC(O)CO)=C(I)C(C(=O)NCC(O)CO)=C1I AMDBBAQNWSUWGN-UHFFFAOYSA-N 0.000 description 1
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
- MHABMANUFPZXEB-UHFFFAOYSA-N O-demethyl-aloesaponarin I Natural products O=C1C2=CC=CC(O)=C2C(=O)C2=C1C=C(O)C(C(O)=O)=C2C MHABMANUFPZXEB-UHFFFAOYSA-N 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- XMMFBEWONDCTLD-UHFFFAOYSA-N acetyl(dimethyl)azanium;chloride Chemical compound Cl.CN(C)C(C)=O XMMFBEWONDCTLD-UHFFFAOYSA-N 0.000 description 1
- 125000002252 acyl group Chemical group 0.000 description 1
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 1
- 150000001342 alkaline earth metals Chemical class 0.000 description 1
- 230000009435 amidation Effects 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 238000009903 catalytic hydrogenation reaction Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000007810 chemical reaction solvent Substances 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 239000013058 crude material Substances 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 229960004537 ioversol Drugs 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- QQVIHTHCMHWDBS-UHFFFAOYSA-N isophthalic acid Chemical compound OC(=O)C1=CC=CC(C(O)=O)=C1 QQVIHTHCMHWDBS-UHFFFAOYSA-N 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 229910052744 lithium Inorganic materials 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000001280 n-hexyl group Chemical group C(CCCCC)* 0.000 description 1
- 125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 238000007709 nanocrystallization Methods 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 238000005580 one pot reaction Methods 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 238000006053 organic reaction Methods 0.000 description 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 235000007686 potassium Nutrition 0.000 description 1
- 229910000027 potassium carbonate Inorganic materials 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- IMFACGCPASFAPR-UHFFFAOYSA-N tributylamine Chemical compound CCCCN(CCCC)CCCC IMFACGCPASFAPR-UHFFFAOYSA-N 0.000 description 1
- YFTHZRPMJXBUME-UHFFFAOYSA-N tripropylamine Chemical compound CCCN(CCC)CCC YFTHZRPMJXBUME-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C231/00—Preparation of carboxylic acid amides
- C07C231/02—Preparation of carboxylic acid amides from carboxylic acids or from esters, anhydrides, or halides thereof by reaction with ammonia or amines
Definitions
- the present invention generally relates to a process for the preparation of non ionic iodinated contrast agents and, in more details, it relates to a process for the preparation of Iopamidol in high yields and with a high degree of purity.
- Iopamidol, as well as others non ionic iodinated contrast agents, is employed in the diagnostic field in the X- ray imagine techniques.
- N,N'-Bis[2-hydroxy- 1 -(hydroxymethyl)ethyl]-5-[[(2S)-2-hydroxy- 1 -oxopropyl]- amino]-2,4,6-triiodo-l,3-benzendicarboxamide (see the formula below), generally known as Iopamidol (The Merck Index, XIII Ed., 2001 , Nr. 5073), is a compound broadly used for diagnostic methodologies:
- aliphatic tertiary amines such as, for instance, triethylamine, tripropylamine, tributylamine and diisopropylethylamine.
- inorganic bases such as e.g. dimethylacetamide (DMA).
- F-impurity is within the list of possible side-products generated from the synthesis of iopamidol (e.g. see European Pharmacopoeia 6.0 Ed. 01/2008:1115).
- the process of the present invention enables for the preparation of iopamidol with a particularly low amount of F-impurity as well as others side-products, whilst using inorganic bases. All the above allows for the removal of such side products by ordinary purification steps, so to collect the final product within the imposed limitations, as previously indicated
- alkaline or alkaline-rare earth metal oxide or hydroxide mean the lithium, potassium, magnesium or calcium oxides or hydroxides.
- oxides particularly preferred are the calcium and magnesium oxides.
- the reaction is performed in the presence of sodium or calcium hydroxide, and even more preferably, in the presence of calcium hydroxide.
- hydroxide is carried out according to those techniques conventionally employed in industrial applications, i.e. by adding a suitable amount of the selected base, either in a solid form or as an aqueous solution.
- Said addition is performed by a single addition or, alternatively, portion-wise, up to the achievement of the necessary amount of hydroxide.
- the selected base is employed in a ratio of at least 2:1 (equivalents) compared to the amount of compound (II) [i.e. in a ratio of 1 :1 (equivalents), compared to the amount of 2-amino-l,3-propandiol] and more preferably in excess.
- the base may be added to the solution of compound (II) either previously, or at the same time, or even after, the addition of 2- amino- 1 ,3-propandiol.
- the mixture is conveniently stirred, according to the common procedures as industrially employed.
- the addition of both the 2-amino-l,3- propandiol and the base is performed gradually, by monitoring the reaction mixture temperature, being said temperature kept under about 30 0 C.
- reaction is carried out in the presence of an aprotic dipolar organic solvent, preferably dimethylacetamide (DMA).
- DMA dimethylacetamide
- the starting material i.e. compound of formula (II)
- compound of formula (II) is a known compound, and, in case, it can be prepared according to the above scheme, starting from the corresponding 5-amino-2,4,6-triiodoisophtalic acid dichloride of formula (I).
- the compound of formula (III) may be obtained according to the process object of the present invention, either starting from compound of formula (II) as such, or, optionally, starting from the corresponding compound of formula (I), without the needing of isolate the intermediate of formula (II), thus formed.
- the condensation reaction between the 5-amino-2,4,6-triiodoisophtalic acid dichloride of formula (I) and (S)-[2-(acetyloxy)]propionic acid dichloride, as per step (a), is accomplished following methods known in the art, preferably in DMA as possible aprotic dipolar organic solvent.
- reaction mixture is then directly added with the selected alkaline or alkaline rare-earth metal oxide or hydroxide along with the suitable amount of 2-amino- 1,3-propandiol, in a manner as previously reported.
- the amount of base to be employed is remarkably higher.
- the base is employed not only for the neutralization of the acid formed during the reaction of amidation between 5-amino-2,4,6-triiodoisophtalic acid dichloride (I) and (S)-[2-(acetyloxy)]propionic acid dichloride, but also for the neutralization of the acid that may arise from the possible excess of (S)-[2- (acetyloxy)]propionic acid dichloride, and, also, for the neutralization of the acid formed during the amidation reaction between compound (II) and 2-amino-l,3- propandiol.
- the selected base when the present process is carried out without isolation of the intermediate(II), is employed in a ratio of at least 3:1 (equivalents) respect to the amount of 5-amino-2,4,6- triiodoisophtalic acid dichloride of formula (I), and more preferably in excess.
- the addition of the base to the reaction system is performed before the addition of 2-amino-l,3-propandiol actually occurs.
- the addition of the reactives e.g. the addition of the hydroxide or oxide, either in a solid form or as aqueous solution, and the 2-amino-l,3-propandiol, is preferably effected slowly or portion-wise, under stirring and keeping the temperature below about 30 0 C.
- the addition of the base to the crude reaction material, which contains the intermediate of formula (II), is conducted at a temperature between about 5°C and about 20 0 C.
- the thus obtained compound of formula (III), either starting from the isolated compound of formula (II) or starting from the corresponding precursor of formula (I), is afterwards converted in iopamidol (IV), by operating according to the methods known in literature.
- compound of formula (III) is first isolated from the crude reaction material, purified, optionally by a passage through ionic exchange resins, and then hydrolyzed under basic conditions for the cleavage of the acetyl group.
- a further object of the present invention a process for the preparation of iopamidol (IV) comprising the basic hydrolysis of the corresponding acetyl iopamidol of formula (III), being said compound of formula (III) prepared as previously indicated, i.e.
- the process in object leads to the desired product in high yield and with a high degree of purity.
- the amount of the existing impurities, and among them the F-impurity as mentioned above, is particularly low so that said impurities may be removed, by conventional purification methodologies.
- the present process may have a general industrial applicability and may be advantageously applied in the preparation of other iodinated non ionic contrast agents, which synthesis contemplate the condensation reaction between a suitable derivative of the dichloride of the 5-amino-2,4,6-triiodoisophtalic acid and an aminoalcohol. It is therefore an additional object of the present invention a process for the preparation of a compound of formula (VII) comprising the condensation reaction between the acid dichloride of formula (V) with an aminoalcohol of formula (VI), being said reaction carried out in an aprotic dipolar solvent and in the presence of an alkaline or rare-earth alkaline metal oxide or hydroxide
- R is a linear or branched alkyl group with 1 to 6 carbon atoms, optionally substituted by one or more hydroxy groups optionally in a protected form, being said alkyl group optionally interrupted by one or more hetero atoms selected from -O- and -NH-;
- Ri is a hydrogen atom or it has one of the meanings of R;
- R 2 is a linear or branched alkyl group with 1 to 4 carbon atoms, substituted by at least one hydroxy group;
- R 3 is a hydrogen atom or has one of the meanings of R 2 .
- linear or branched alkyl group with 1 to 6 carbon atoms means those groups such as, for instance, methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, n-pentyl, n-hexyl, and the like.
- Said alkyl group is optionally substituted by one or more hydroxy groups as such, or preferably, in a protected form.
- protected form we intend that the hydroxy group is conveniently protected by a suitable moiety which is responsible for the preservation of the subjected group, during the course of the reaction, to be subsequently removed according to known methods, so to cleave the hydroxy group back to the original form.
- the hydroxy group is preferably protected by an acyl group, e.g. acetyl (-COCH3), so that the corresponding acetoxy moiety (-OCOCH 3 ) is thus formed.
- an acyl group e.g. acetyl (-COCH3)
- the aminoalcohol of formula (VI) is preferably selected from 2- amino-l,3-propandiol or 3-amino-l,2-propandiol, so that the group R 2 corresponds to [- CH(CH 2 OH) 2 or -CH 2 CHOHCH 2 OH], respectively.
- the aprotic dipolar organic solvent the proper oxide or hydroxide, as well as the major process parameters, see what previously described.
- reaction mixture On completion of the reaction, the reaction mixture is properly diluted with a supplementary amount of solvent and optionally cooled, e.g. at about 15°C.
- a suitable amount of selected base for instance powdered calcium hydroxide, along with a proper amount of 2-amino-l,3-propandiol are thus added.
- the mixture is finally kept under stirring overnight at the selected temperature, e.g. at about 30 0 C, up to the completion of the reaction.
- the obtained raw material is distilled under vacuum to remove the most of the solvent, and the residual crude is diluted with water and purified by means of a cationic resin, according to conventional techniques.
- the eluted material, containing the product of formula (III), is then hydrolyzed under basic conditions and, at the completion of the reaction, the mixture is adjusted to a pH substantially neutral (i.e. around 7).
- the resulting mixture which contains iopamidol (IV) is finally purified by known methods, comprising, for instance, purification through resins, nano- filtration and crystallization in the presence of a suitable alcohol, such as, e.g., 2-butanol.
- a suitable alcohol such as, e.g., 2-butanol.
- the crude reaction material containing the derivative of formula (III) may be purified and hydro lyzed according to the procedure of the following Example 3.
- the crude reaction mixture was then distilled under vacuum (95°C, 10 mbar, 7.5 mmHg) to remove the most of the solvent, up to the obtainment of a viscous residue.
- the hot residue was then treated with deionised water (1455 g) and the pH was adjusted to 1.7 by addition of hydrochloric acid (33 g, 34% w/w).
- the resulting solution was eluted through 1500 mL of a strong cationic exchange resin (Dowex C350TM by DOW) in the Na + form, to remove the Ca 2+ ions, along with the excess of 2-amino-l,3-propandiol.
- the eluted solution was afterward treated with a solution of sodium hydroxide (250 g, 30%) and kept at about 35°C for 7 hours, in order to hydro lyse the acetic ester.
- the pH was then adjusted at a value of about 7 by addition of hydrochloric acid and the resulting solution was treated with sodium sulphite (0.25 g), purified on a PS-DVB resin (1300 mL, Amberlite XAD 100TM by Rohm and Haas) and then desalted by nano- filtration.
- the final desalting step was performed by a series of two resin plates comprising 425 mL of a strong cationic exchange resin in the H + form (Dowex C350TM) and 500 mL of weak anionic exchange resin (Re lite MG1 ® by Mitsubishi).
- the resulting solution was then concentrated under vacuum, obtaining by that a water content of 30% w/w, and the residue was crystallized from 2-butanol (1250 g).
- the crystallization was completed by adding a suitable aliquot of 2-butanol and by simultaneously distilling off the azeotrope at atmospheric pressure, up to a water content in the suspension close to 3% w/w.
- the product was filtered and dried under vacuum at about 50 0 C, to obtain iopamidol (591 g, 90.0% of yield, starting from compound (II).
- the thus obtained iopamidol satisfied the purity specifications as required.
- Example 5 The procedure of the Example 5 was modified by operating at a lower temperature, as described herein below.
- the crude reaction material was then distilled under vacuum (95°C, 10 mbar, 7,5 mmHg) to remove the most of the solvent, until the formation of a viscous residue.
- the hot residue was hence treated with deionised water (1460 g) and the pH was adjusted to 2 by addition of hydrochloric acid (108 g, 34% w/w).
- the eluted was then treated with a solution of sodium hydroxide (260 g, 30%) and maintained at 35°C for 7 hours to hydrolyze the acetic ester.
- the pH was adjusted to 7 by addition of hydrochloric acid and the resulting solution was treated with sodium sulphite (0,25 g), purified on a PS-DVB resin (1300 mL, Amberlite XAD1600TM by Rohm and Haas) and therefore desalted by nano-filtration.
- the final desalting step was performed by a series of two resin plates comprising 425 mL of a strong cationic exchange resin in the H + form (Dowex C350TM) and 500 mL of a week anionic exchange resin (Relite MG1 ® by Mitsubishi).
- the resulting solution was then concentrated under vacuum until the obtainment of a water content of about 30% w/w, and the residue was then crystallized from 2-butanol (1250 g).
- the crystallization was completed by adding 2-butanol and simultaneously distilling off the azeotrope at atmospheric pressure until the water content in the suspension was about 3% w/w.
- the product was filtered and dried under vacuum at about 50 0 C, to obtain iopamidol (576 g, 87.3% yield starting from compound II ).
- the iopamidol thus obtained satisfies the purity specifications as required.
- Example 8 The same procedure as the previous Example 7 was followed, with the exception that calcium hydroxide was replaced by a same molar amount of calcium oxide. Iopamidol was obtained with 83.0% yield starting from compound II and satisfies the purity specifications as required.
- Example 8
- Example 5 The same procedure as the previous Example 5 was modified by using sodium carbonate in place of calcium hydroxide, as follow. 423 g of the crude reaction material in DMA as per Example 4 (0.25 theoretical mol of compound II) was diluted with DMA (200 g) and the mixture was cooled at -5°C.
- Example 5 The procedure as per Example 5 was modified by using trietilamine in place of calcium hydroxide as follow. 423 g of the crude reaction material in DMA as per Example 4 (0.25 theoretical mol of compound II) was diluted with DMA (199 g) and the mixture was cooled at a temperature of about -5°C. Triethylamine (114 g, 1.13 mol) was then slowly added to the reaction mixture, under stirring and keeping the temperature lower than 5 0 C. After that, a solution of 2-amino-l,3-propandiol in DMA (231 g, 24% w/w, 0.61 mol) was added over 1 hour. The mixture was then heated at 70 0 C and maintained in such conditions for 3 hours until the completion of the reaction. By operating in an analogue manner as Example 3, iopamidol (IV) was thus obtained by purification and hydrolysis of the compound of formula (III).
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Priority Applications (16)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
BRPI0921464A BRPI0921464B8 (pt) | 2008-11-18 | 2009-11-02 | processo para preparação de agente de contraste iodado |
RU2011124888/04A RU2493146C2 (ru) | 2008-11-18 | 2009-11-02 | Способ получения йодированного контрастного агента |
CA2743079A CA2743079C (en) | 2008-11-18 | 2009-11-02 | Process for the preparation of iodinated contrast agent |
MX2011005236A MX2011005236A (es) | 2008-11-18 | 2009-11-02 | Proceso para la preparacion de agente de contraste yodado. |
ES09744402.0T ES2637010T3 (es) | 2008-11-18 | 2009-11-02 | Proceso para la preparación de agente de contraste yodado |
AU2009317450A AU2009317450B2 (en) | 2008-11-18 | 2009-11-02 | Process for the preparation of iodinated contrast agent |
JP2011536812A JP5536087B2 (ja) | 2008-11-18 | 2009-11-02 | ヨウ化造影剤の製造方法 |
US13/127,804 US8624061B2 (en) | 2008-11-18 | 2009-11-02 | Process for the preparation of iodinated contrast agent |
SI200931735T SI2365963T1 (sl) | 2008-11-18 | 2009-11-02 | Postopek priprave jodiranih kontrastnih sredstev |
CN200980145584.9A CN102216259B (zh) | 2008-11-18 | 2009-11-02 | 制备碘化的造影剂的方法 |
DK09744402.0T DK2365963T3 (en) | 2008-11-18 | 2009-11-02 | PROCEDURE FOR THE PREPARATION OF IODATED CONTRACTOR |
KR1020117011238A KR101668042B1 (ko) | 2008-11-18 | 2009-11-02 | 요오드화된 조영제의 제조방법 |
PL09744402T PL2365963T3 (pl) | 2008-11-18 | 2009-11-02 | Sposób przygotowywania jodowanych środków kontrastowych |
EP09744402.0A EP2365963B1 (en) | 2008-11-18 | 2009-11-02 | Process for the preparation of iodinated contrast agent |
IL212907A IL212907A (en) | 2008-11-18 | 2011-05-16 | A method of producing contrast material containing iodine |
HRP20171443TT HRP20171443T1 (hr) | 2008-11-18 | 2017-09-26 | Postupak za pripremanje jodiranog kontrastnog sredstva |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
ITMI20082042 | 2008-11-18 | ||
ITMI2008A002042 | 2008-11-18 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2010057765A1 true WO2010057765A1 (en) | 2010-05-27 |
Family
ID=40940416
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/EP2009/064413 WO2010057765A1 (en) | 2008-11-18 | 2009-11-02 | Process for the preparation of iodinated contrast agent |
Country Status (19)
Country | Link |
---|---|
US (1) | US8624061B2 (pt) |
EP (1) | EP2365963B1 (pt) |
JP (1) | JP5536087B2 (pt) |
KR (1) | KR101668042B1 (pt) |
CN (1) | CN102216259B (pt) |
AU (1) | AU2009317450B2 (pt) |
BR (1) | BRPI0921464B8 (pt) |
CA (1) | CA2743079C (pt) |
DK (1) | DK2365963T3 (pt) |
ES (1) | ES2637010T3 (pt) |
HR (1) | HRP20171443T1 (pt) |
HU (1) | HUE034436T2 (pt) |
IL (1) | IL212907A (pt) |
MX (1) | MX2011005236A (pt) |
PL (1) | PL2365963T3 (pt) |
PT (1) | PT2365963T (pt) |
RU (1) | RU2493146C2 (pt) |
SI (1) | SI2365963T1 (pt) |
WO (1) | WO2010057765A1 (pt) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
RU2481325C2 (ru) * | 2008-12-05 | 2013-05-10 | Даевунг Фармасьютикал Ко., Лтд. | Способ селективной кристаллизации z-изомера иопромида |
GB2496971A (en) * | 2011-11-25 | 2013-05-29 | Ge Healthcare As | Preparation of X-ray contrast agents |
US9950991B2 (en) | 2013-11-05 | 2018-04-24 | Bracco Imaging S.P.A. | Process for the preparation of iopamidol |
WO2018104228A1 (en) | 2016-12-05 | 2018-06-14 | Bracco Imaging Spa | Mechanochemical synthesis of radiographic agents intermediates |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PT108524B (pt) * | 2015-06-02 | 2017-12-15 | Hovione Farmaciência S A | Processo para a preparação de intermediários úteis na preparação de agentes de contraste não-iónicos |
CN106831480B (zh) * | 2015-12-07 | 2019-01-15 | 北京大学 | 基于碘帕醇脂质衍生物的造影剂及其制备方法与用途 |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB1472050A (en) * | 1974-12-13 | 1977-04-27 | Savac Ag | Non-ionic x-ray contrast agents |
US4364921A (en) * | 1979-03-08 | 1982-12-21 | Schering, Aktiengesellschaft | Novel triiodinated isophthalic acid diamides as nonionic X-ray contrast media |
WO1998024757A1 (en) * | 1996-12-04 | 1998-06-11 | Dibra S.P.A. | A process for the preparation of 5-amino-2,4,6-triiodo-1,3-benzenedicarboxylic acid derivatives |
WO1998054124A1 (en) * | 1997-05-30 | 1998-12-03 | Bracco S.P.A. | A process for the preparation of 5-[acetyl (2,3-dihydroxypropyl)amino]-n,n'-bis (2,3-dihydroxypropyl)-2,4,6- triiodo-1,3-benzenedicarboxamide |
WO1999058494A2 (en) * | 1998-05-08 | 1999-11-18 | Dibra S.P.A. | Process for the preparation of s- n,n'- bis[2- hydroxy-1- (hydroxymethyl) ethyl]-5- [(2- hydroxy-1- oxopropyl)- amino]- 2,4,6- triiodo- 1,3- benzenedicarboxamide |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3835121A (en) * | 1972-07-18 | 1974-09-10 | Essex International Inc | Theic-hydantoin-ester resins for wire coatings |
US4396598A (en) * | 1982-01-11 | 1983-08-02 | Mallinckrodt, Inc. | Triiodoisophthalamide X-ray contrast agent |
US4822890A (en) * | 1983-05-20 | 1989-04-18 | Hoffmann-La Roche Inc. | Method for the production of amino terminus protected naturally occurring amino acids |
DE3937118A1 (de) * | 1989-11-03 | 1991-05-08 | Schering Ag | Nichtionische roentgenkontrastmittel mit hohem jodgehalt |
IT1283319B1 (it) * | 1996-03-29 | 1998-04-16 | Zambon Spa | Processo per la preparazione di un intermedio utile nella sintesi di mezzi di contrasto iodurati |
ES2214856T3 (es) * | 1998-05-14 | 2004-09-16 | Cosmoferm B.V. | Proceso para la acilacion de aminoalcoholes. |
IT1319671B1 (it) | 2000-12-01 | 2003-10-23 | Bracco Spa | Processo per la preparazione di (s)-n,n'-bis(2-idrossi-1-(idrossimetil)etil)-5-((2-idrossi-1-ossopropil)ammino) |
JP4402497B2 (ja) * | 2004-03-30 | 2010-01-20 | 大日本印刷株式会社 | イオパミドールの製造方法 |
-
2009
- 2009-11-02 AU AU2009317450A patent/AU2009317450B2/en active Active
- 2009-11-02 DK DK09744402.0T patent/DK2365963T3/en active
- 2009-11-02 CN CN200980145584.9A patent/CN102216259B/zh active Active
- 2009-11-02 MX MX2011005236A patent/MX2011005236A/es active IP Right Grant
- 2009-11-02 JP JP2011536812A patent/JP5536087B2/ja active Active
- 2009-11-02 PL PL09744402T patent/PL2365963T3/pl unknown
- 2009-11-02 ES ES09744402.0T patent/ES2637010T3/es active Active
- 2009-11-02 US US13/127,804 patent/US8624061B2/en active Active
- 2009-11-02 KR KR1020117011238A patent/KR101668042B1/ko active IP Right Grant
- 2009-11-02 CA CA2743079A patent/CA2743079C/en active Active
- 2009-11-02 HU HUE09744402A patent/HUE034436T2/en unknown
- 2009-11-02 WO PCT/EP2009/064413 patent/WO2010057765A1/en active Application Filing
- 2009-11-02 BR BRPI0921464A patent/BRPI0921464B8/pt active IP Right Grant
- 2009-11-02 SI SI200931735T patent/SI2365963T1/sl unknown
- 2009-11-02 EP EP09744402.0A patent/EP2365963B1/en active Active
- 2009-11-02 RU RU2011124888/04A patent/RU2493146C2/ru active
- 2009-11-02 PT PT97444020T patent/PT2365963T/pt unknown
-
2011
- 2011-05-16 IL IL212907A patent/IL212907A/en active IP Right Grant
-
2017
- 2017-09-26 HR HRP20171443TT patent/HRP20171443T1/hr unknown
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB1472050A (en) * | 1974-12-13 | 1977-04-27 | Savac Ag | Non-ionic x-ray contrast agents |
US4364921A (en) * | 1979-03-08 | 1982-12-21 | Schering, Aktiengesellschaft | Novel triiodinated isophthalic acid diamides as nonionic X-ray contrast media |
WO1998024757A1 (en) * | 1996-12-04 | 1998-06-11 | Dibra S.P.A. | A process for the preparation of 5-amino-2,4,6-triiodo-1,3-benzenedicarboxylic acid derivatives |
WO1998054124A1 (en) * | 1997-05-30 | 1998-12-03 | Bracco S.P.A. | A process for the preparation of 5-[acetyl (2,3-dihydroxypropyl)amino]-n,n'-bis (2,3-dihydroxypropyl)-2,4,6- triiodo-1,3-benzenedicarboxamide |
WO1999058494A2 (en) * | 1998-05-08 | 1999-11-18 | Dibra S.P.A. | Process for the preparation of s- n,n'- bis[2- hydroxy-1- (hydroxymethyl) ethyl]-5- [(2- hydroxy-1- oxopropyl)- amino]- 2,4,6- triiodo- 1,3- benzenedicarboxamide |
Non-Patent Citations (1)
Title |
---|
HAAVALDSEN J ET AL: "X-RAY CONTRAST AGENTS. I. SYNTHESIS OF SOME DERIVATIVES OF 5-AMINO-2, 4, 6-TRIIODOISOPHTHLAMIDE", ACTA PHARMACEUTICA SUECICA,, vol. 20, no. 3, 1 January 1983 (1983-01-01), pages 219 - 232, XP002052827, ISSN: 0001-6675 * |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
RU2481325C2 (ru) * | 2008-12-05 | 2013-05-10 | Даевунг Фармасьютикал Ко., Лтд. | Способ селективной кристаллизации z-изомера иопромида |
GB2496971A (en) * | 2011-11-25 | 2013-05-29 | Ge Healthcare As | Preparation of X-ray contrast agents |
US9950991B2 (en) | 2013-11-05 | 2018-04-24 | Bracco Imaging S.P.A. | Process for the preparation of iopamidol |
US10377700B2 (en) | 2013-11-05 | 2019-08-13 | Bracco Imaging S.P.A. | Process for the recovery of a boronic acid |
WO2018104228A1 (en) | 2016-12-05 | 2018-06-14 | Bracco Imaging Spa | Mechanochemical synthesis of radiographic agents intermediates |
US10836710B2 (en) | 2016-12-05 | 2020-11-17 | Bracco Imaging Spa | Mechanochemical synthesis of radiographic agents intermediates |
Also Published As
Publication number | Publication date |
---|---|
US20110207960A1 (en) | 2011-08-25 |
JP5536087B2 (ja) | 2014-07-02 |
IL212907A (en) | 2015-03-31 |
BRPI0921464B8 (pt) | 2021-05-25 |
BRPI0921464A2 (pt) | 2016-01-12 |
IL212907A0 (en) | 2011-07-31 |
CA2743079A1 (en) | 2010-05-27 |
EP2365963A1 (en) | 2011-09-21 |
HUE034436T2 (en) | 2018-02-28 |
KR101668042B1 (ko) | 2016-10-20 |
US8624061B2 (en) | 2014-01-07 |
RU2011124888A (ru) | 2012-12-27 |
DK2365963T3 (en) | 2017-10-09 |
HRP20171443T1 (hr) | 2017-11-03 |
ES2637010T3 (es) | 2017-10-10 |
RU2493146C2 (ru) | 2013-09-20 |
AU2009317450B2 (en) | 2015-05-07 |
PT2365963T (pt) | 2017-08-22 |
BRPI0921464B1 (pt) | 2020-10-06 |
MX2011005236A (es) | 2011-06-16 |
CA2743079C (en) | 2014-03-25 |
KR20110093805A (ko) | 2011-08-18 |
AU2009317450A1 (en) | 2010-05-27 |
EP2365963B1 (en) | 2017-06-28 |
PL2365963T3 (pl) | 2017-12-29 |
SI2365963T1 (sl) | 2017-11-30 |
CN102216259A (zh) | 2011-10-12 |
JP2012509290A (ja) | 2012-04-19 |
CN102216259B (zh) | 2016-01-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP2365963B1 (en) | Process for the preparation of iodinated contrast agent | |
US7173126B2 (en) | Crystalline cefdinir salts | |
JP4219409B2 (ja) | 5―アミノ―2,4,6―トリヨード―1,3―ベンゼンジカルボン酸誘導体を製造する方法 | |
AU2002226359B8 (en) | A process for the preparation of N,N'-substituted 5-amino-1,3-benzenedicarboxamides | |
KR101083147B1 (ko) | 요오헥솔의 제조 방법 | |
KR100612480B1 (ko) | S-n,n'-비스[2-히드록시-1-(히드록시메틸)에틸]-5-[(2-히드록시-1-옥소프로필)-아미노]-2,4,6-트리요오도-1,3-벤젠디카르복사미드의 제조방법 | |
HU228047B1 (en) | A process for the preparation of n,n'-substituted 5-amino-1,3-benzenedicarboxamides | |
EP0854872B1 (en) | Process for the preparation of a disubstituted thiazole | |
JP3539152B2 (ja) | シトシンの製法 | |
US8178722B2 (en) | Method for producing theanine | |
JPH069526A (ja) | 2,4,6−トリヨード−イソフタル酸アミド類の製造方法 | |
JP2022072636A (ja) | アミド化合物の製造方法 | |
JPH08295680A (ja) | アミノチアゾール酢酸誘導体の製造方法 | |
JP2001081083A (ja) | N−炭化水素オキシカルボニルアラニルアミノチアゾール酢酸エステル誘導体の製造方法 | |
JPH1087590A (ja) | カルボン酸アミド化合物の製造方法 | |
JP2004002226A (ja) | 粉末n−長鎖アシルイミノ二塩基酸塩の製造方法 | |
JPH08176128A (ja) | チアゾール酢酸の製造方法 | |
EP1963309A1 (en) | Method for producing metal salts of losartan |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 200980145584.9 Country of ref document: CN |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 09744402 Country of ref document: EP Kind code of ref document: A1 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2009317450 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 13127804 Country of ref document: US |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2743079 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 3285/CHENP/2011 Country of ref document: IN |
|
WWE | Wipo information: entry into national phase |
Ref document number: 212907 Country of ref document: IL |
|
ENP | Entry into the national phase |
Ref document number: 20117011238 Country of ref document: KR Kind code of ref document: A |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2011536812 Country of ref document: JP Ref document number: MX/A/2011/005236 Country of ref document: MX |
|
ENP | Entry into the national phase |
Ref document number: 2009317450 Country of ref document: AU Date of ref document: 20091102 Kind code of ref document: A |
|
REEP | Request for entry into the european phase |
Ref document number: 2009744402 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2009744402 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2011124888 Country of ref document: RU |
|
ENP | Entry into the national phase |
Ref document number: PI0921464 Country of ref document: BR Kind code of ref document: A2 Effective date: 20110518 |